NCX 1000
Based on 1 Customer Validation
NCX 1000 is a liver-specific NO donor compound derived from ursodeoxycholic acid (UDCA).
For research use only. We do not sell to patients.
- Purity: 98.91%
- CAS No.: 401519-96-8
- Formula: C38H55NO10
- Molecular Weight:685.84
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 401519-96-8
-
Appearance Solid
-
Molecular Weight 685.84
-
Formula C38H55NO10
-
Color White to off-white
-
SMILES
C[C@H](CCC(OC1=CC=C(/C=C/C(OCCCCO[N+]([O-])=O)=O)C=C1OC)=O)[C@H]2CC[C@@]3([H])[C@]4([H])[C@@H](O)C[C@]5([H])C[C@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]23C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 100 mg/mL (145.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Rats: On the first protocol, 54 rats, 12 animals/group unless specified, are randomly allocated to receive one of the following treatments: group 1 has phenobarbital induction and no further treatment; group 2 (16 animals) is treated with CCl4 twice a week for 8 weeks; group 3 has CCl4 twice a week plus UDCA (15 mg/kg); and group 4 has CCl4 twice a week plus NCX-1000 (15 mg/kg). NCX-1000 and UDCA are dissolved in carboxymethyl cellulose and administered daily by gavage. Animal weight is monitored daily through the study period, and the dosage of CCl4 is adjusted accordingly to the animal weight. At the end of the treatment surviving animals are killed by an overdose of uretane, and blood, ascitic fluid, and livers are collected. A portion of each liver is fixed in 10% formalin for histological evaluation. The remaining tissue is partitioned and immediately stored under frozen liquid nitrogen at -80°C until used. On the second protocol, 74 rats are randomly allocated to receive the same treatments as protocol 1. At the end of the study, surviving animals are tested for portal and arterial pressure measurement.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fiorucci S, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8897-902. Epub 2001 Jul 10. [Content Brief]
[2]. Fiorucci S, et al. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol. 2003 Dec;39(6):932-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4581 mL | 7.2903 mL | 14.5807 mL | 36.4516 mL |
| 5 mM | 0.2916 mL | 1.4581 mL | 2.9161 mL | 7.2903 mL | |
| 10 mM | 0.1458 mL | 0.7290 mL | 1.4581 mL | 3.6452 mL | |
| 15 mM | 0.0972 mL | 0.4860 mL | 0.9720 mL | 2.4301 mL | |
| 20 mM | 0.0729 mL | 0.3645 mL | 0.7290 mL | 1.8226 mL | |
| 25 mM | 0.0583 mL | 0.2916 mL | 0.5832 mL | 1.4581 mL | |
| 30 mM | 0.0486 mL | 0.2430 mL | 0.4860 mL | 1.2151 mL | |
| 40 mM | 0.0365 mL | 0.1823 mL | 0.3645 mL | 0.9113 mL | |
| 50 mM | 0.0292 mL | 0.1458 mL | 0.2916 mL | 0.7290 mL | |
| 60 mM | 0.0243 mL | 0.1215 mL | 0.2430 mL | 0.6075 mL | |
| 80 mM | 0.0182 mL | 0.0911 mL | 0.1823 mL | 0.4556 mL | |
| 100 mM | 0.0146 mL | 0.0729 mL | 0.1458 mL | 0.3645 mL |
NCX 1000 Related Classifications
HY-U00023 Related Classifications
Powered by Bioz